公开(公告)号：US10472376B2

公开(公告)日：2019-11-12

申请号：US14902388

申请日：2014-07-02

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Satoshi Yamamoto ,  Junya Shirai ,  Mitsunori Kono ,  Yoshihide Tomata ,  Ayumu Sato ,  Atsuko Ochida ,  Yoshiyuki Fukase ,  Shoji Fukumoto ,  Tsuneo Oda ,  Hidekazu Tokuhara ,  Naoki Ishii ,  Yusuke Sasaki

IPC: C07F7/08 ,  C07D309/06 ,  C07D405/12 ,  C07D239/36 ,  C07D413/12 ,  C07D205/04 ,  C07C237/22 ,  C07D207/12 ,  C07D271/10 ,  C07F7/10 ,  C07F7/30 ,  C07K5/065 ,  C07D309/08 ,  C07D231/12 ,  C07D231/56 ,  C07D333/38 ,  C07D233/72 ,  C07D403/06 ,  C07D237/14 ,  C07D239/54 ,  C07K5/087

Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.

公开(公告)号：US10000488B2

公开(公告)日：2018-06-19

申请号：US15510225

申请日：2015-09-10

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Satoshi Yamamoto ,  Junya Shirai ,  Tsuneo Oda ,  Takashi Imada ,  Mitsunori Kono ,  Ayumu Sato ,  Yoshihide Tomata ,  Atsuko Ochida ,  Naoki Ishii ,  Yusuke Sasaki ,  Yoshiyuki Fukase ,  Tomoya Yukawa ,  Shoji Fukumoto

IPC: C07D471/04 ,  C07D401/14 ,  C07D413/12 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D239/96 ,  C07D409/14 ,  C07D403/12 ,  C07D401/12 ,  C07D417/14 ,  C07D417/12

CPC classification number: C07D471/04 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61P1/00 ,  A61P11/00 ,  C07D239/96 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

公开(公告)号：US12171777B2

公开(公告)日：2024-12-24

申请号：US18310467

申请日：2023-05-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61K31/7076 ,  A61K47/68 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US11666594B2

公开(公告)日：2023-06-06

申请号：US17065242

申请日：2020-10-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato Yoshikawa ,  Morihisa Saitoh ,  Taisuke Kato ,  Yayoi Nakayama ,  Tomohiro Seki ,  Yasuo Nakagawa ,  Yusuke Tominari ,  Masaki Seto ,  Yusuke Sasaki ,  Masanori Okaniwa ,  Tsuneo Oda ,  Akito Shibuya ,  Kosuke Hidaka ,  Zenyu Shiokawa ,  Shumpei Murata ,  Atsutoshi Okabe ,  Yoshihisa Nakada ,  Michiyo Mochizuki ,  Brian Scott Freeze ,  Taisuke Tawaraishi ,  Yasufumi Wada ,  Paul D. Greenspan

IPC: A61K31/7084 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02 ,  A61K47/68 ,  A61K31/7076

CPC classification number: A61K31/7084 ,  A61K31/7076 ,  A61K47/6807 ,  A61P35/00 ,  C07H21/00 ,  C07H21/02

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases.
The present disclosure relates to a compound represented by the formula (I):




wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US10774083B2

公开(公告)日：2020-09-15

申请号：US16333296

申请日：2017-09-14

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takaharu Hirayama ,  Yasuhiro Hirata ,  Yusuke Tominari ,  Naoki Iwamura ,  Yusuke Sasaki ,  Moriteru Asano ,  Terufumi Takagi ,  Masanori Okaniwa ,  Shinichi Imamura

IPC: C07D401/04 ,  C07D401/14 ,  C07D473/28 ,  C07D405/14 ,  C07D413/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D473/40 ,  C07D519/00 ,  A61P35/00 ,  A61K31/506 ,  A61K31/444 ,  A61K31/4439 ,  C07D473/00 ,  C07D473/32 ,  A61K31/5377 ,  A61K31/501 ,  A61K31/52 ,  A61P43/00 ,  A61K31/437 ,  C12N9/99

Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US09890145B2

公开(公告)日：2018-02-13

申请号：US15137161

申请日：2016-04-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masato Yoshida ,  Kazuaki Takami ,  Yusuke Tominari ,  Zenyu Shiokawa ,  Akito Shibuya ,  Yusuke Sasaki ,  Tony Gibson ,  Terufumi Takagi

IPC: C07D401/14 ,  C07D487/04 ,  C07D417/14 ,  C07D487/10 ,  A61P37/00 ,  C07D403/14 ,  A61K31/4155 ,  C07D413/14 ,  C07D401/04 ,  C07D409/14 ,  C07D405/14 ,  A61K9/06 ,  A61K9/20 ,  A61K9/48 ,  C07D403/04 ,  C07D471/04 ,  C07D471/10 ,  C07D491/107 ,  C07D495/04

CPC classification number: C07D413/14 ,  A61K9/06 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4858 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D495/04

Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US11851449B2

公开(公告)日：2023-12-26

申请号：US17316185

申请日：2021-05-10

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Satoshi Yamamoto ,  Junya Shirai ,  Mitsunori Kono ,  Yoshihide Tomata ,  Ayumu Sato ,  Atsuko Ochida ,  Yoshiyuki Fukase ,  Shoji Fukumoto ,  Tsuneo Oda ,  Hidekazu Tokuhara ,  Naoki Ishii ,  Yusuke Sasaki

IPC: C07F7/08 ,  C07D205/04 ,  C07D207/12 ,  C07K5/065 ,  C07D239/36 ,  C07D213/64 ,  C07D309/06 ,  C07D333/38 ,  C07F7/10 ,  C07D403/06 ,  C07D271/10 ,  C07C237/22 ,  C07D295/14 ,  C07D207/26 ,  C07D413/12 ,  C07F7/30 ,  C07D233/72 ,  C07D309/08 ,  C07D231/56 ,  C07D261/08 ,  C07D209/18 ,  C07D405/12 ,  C07D261/12 ,  C07D239/54 ,  C07D211/62 ,  C07D237/14 ,  C07D231/12 ,  C07D487/04 ,  A61P43/00 ,  A61P29/00 ,  A61P25/00 ,  A61P19/02 ,  A61P17/06 ,  A61P1/04 ,  C07K5/087

CPC classification number: C07F7/0812 ,  A61P1/04 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P29/00 ,  A61P43/00 ,  C07C237/22 ,  C07D205/04 ,  C07D207/12 ,  C07D207/26 ,  C07D209/18 ,  C07D211/62 ,  C07D213/64 ,  C07D231/12 ,  C07D231/56 ,  C07D233/72 ,  C07D237/14 ,  C07D239/36 ,  C07D239/54 ,  C07D261/08 ,  C07D261/12 ,  C07D271/10 ,  C07D295/14 ,  C07D309/06 ,  C07D309/08 ,  C07D333/38 ,  C07D403/06 ,  C07D405/12 ,  C07D413/12 ,  C07D487/04 ,  C07F7/081 ,  C07F7/10 ,  C07F7/30 ,  C07K5/06078 ,  C07K5/0812

Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.

公开(公告)号：US11053262B2

公开(公告)日：2021-07-06

申请号：US16576293

申请日：2019-09-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Satoshi Yamamoto ,  Junya Shirai ,  Mitsunori Kono ,  Yoshihide Tomata ,  Ayumu Sato ,  Atsuko Ochida ,  Yoshiyuki Fukase ,  Shoji Fukumoto ,  Tsuneo Oda ,  Hidekazu Tokuhara ,  Naoki Ishii ,  Yusuke Sasaki

IPC: C07F7/08 ,  C07D309/06 ,  C07D405/12 ,  C07D239/36 ,  C07D413/12 ,  C07D205/04 ,  C07C237/22 ,  C07D207/12 ,  C07D271/10 ,  C07F7/10 ,  C07F7/30 ,  C07K5/065 ,  C07D309/08 ,  C07D231/12 ,  C07D231/56 ,  C07D333/38 ,  C07D233/72 ,  C07D403/06 ,  C07D237/14 ,  C07D239/54 ,  C07D213/64 ,  C07D295/14 ,  C07D207/26 ,  C07D261/08 ,  C07D209/18 ,  C07D261/12 ,  C07D211/62 ,  C07D487/04 ,  A61P43/00 ,  A61P29/00 ,  A61P25/00 ,  A61P19/02 ,  A61P17/06 ,  A61P1/04 ,  C07K5/087

Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.

公开(公告)号：US10800754B2

公开(公告)日：2020-10-13

申请号：US16332993

申请日：2017-09-14

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takaharu Hirayama ,  Yasuhiro Hirata ,  Yusuke Tominari ,  Naoki Iwamura ,  Yusuke Sasaki ,  Moriteru Asano ,  Terufumi Takagi ,  Masanori Okaniwa ,  Masato Yoshida ,  Shinichi Imamura

IPC: C07D401/04 ,  C07D401/14 ,  C07D407/14 ,  C07D409/14 ,  C07D417/14 ,  A61P35/00

Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US09321757B2

公开(公告)日：2016-04-26

申请号：US14533326

申请日：2014-11-05

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masato Yoshida ,  Kazuaki Takami ,  Yusuke Tominari ,  Zenyu Shiokawa ,  Akito Shibuya ,  Yusuke Sasaki ,  Tony Gibson ,  Terufumi Takagi

IPC: C07D401/14 ,  C07D487/04 ,  C07D417/14 ,  C07D487/10 ,  A61P37/00 ,  C07D403/14 ,  A61K31/4155 ,  C07D413/14 ,  C07D409/14 ,  C07D405/14 ,  C07D401/04 ,  A61K9/06 ,  A61K9/20 ,  A61K9/48

CPC classification number: C07D413/14 ,  A61K9/06 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4858 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D495/04

Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有IRAK-4抑制作用的杂环化合物，其可用于预防或治疗炎性疾病，自身免疫性疾病，骨关节炎性退行性疾病，肿瘤性疾病等，以及含有它们的药物。 本发明涉及由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐。